Ascentage Pharma Gr-adr (AAPG) — Institutional Holders Breakdown (Q2 2026)

AAPG ranks #10590 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AAPG is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

8 institutions disclose a position in AAPG, but none treat it as a major bet — even Point72 Asset Management, L.P., its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Morgan Stanley has added to its AAPG position for two straight quarters, increasing it by $12.1K to reach $16.1K today.

Steve Cohen has trimmed its AAPG position for two straight quarters, cutting it by $195.8K while still holding $243.0K.

AAPG reported a net loss of $1.2B in its latest fiscal year.

• Not yet profitable — net loss of $1.2B in the latest fiscal year
• Revenue declined 41.5% year over year
• Net income declined year over year, from -$405.7M to -$1.2B
• Operating cash flow was negative, using $1.2B in cash
• Current ratio of 1.79x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.97x equity — within a conventional range